Navigation Links
HealthCare Technologies Ltd. (NASDAQ: HCTL) Announces Receipt of NASDAQ Delisting Notice
Date:1/10/2008

NEW YORK, January 10 /PRNewswire-FirstCall/ -- HealthCare Technologies Ltd., (the "Company") today announced that it received a letter dated January 7, 2008 from the Staff of the Listing Qualifications Department (the "Staff Determination") of The NASDAQ Stock Market LLC, which indicated that because the Staff believes that the Company's Plan of Arrangement with NexGen Biofuels, Inc., which closed on December 31, 2007, constituted a reverse merger, the surviving entity is required to submit an initial listing application and satisfy Nasdaq's initial listing standards. On September 7, 2007, NexGen Biofuels, Ltd. submitted its listing application. However, the application was not approved because, among other things, the Company did not meet the minimum $4 bid price requirement for initial listing. Accordingly, the Company's securities will be delisted from The NASDAQ Stock Market. In that regard, unless the Company requests an appeal of this determination, NASDAQ will suspend trading of the Company's securities on the Capital Market at the opening of business on January 16, 2008.

In response, the Company intends to timely request a hearing before a NASDAQ Listing Qualifications Panel to address the Staff Determination and seek continued listing in accordance with applicable NASDAQ rules. The Company's hearing request will stay any delisting action pending the issuance of a decision by the Panel following the hearing.

In the event that the Company's appeal is unsuccessful, the Company believes that its ordinary shares will be eligible for trading on the OTC Bulletin Board, subject to the filing of a Form 211 by a market maker.

For more information on NexGen Biofuels, visit http://www.nexgenbiofuels.net

SAFE HARBOR: This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward looking statement made by or on behalf of HealthCare Technologies Ltd. Readers are referred to the documents filed by the company with the Securities and Exchange Commission, specifically the Form 8-K filed on January 7, 2008 that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

FOR: HealthCare Technologies Ltd.

CONTACT: Eran Rotem CFO

+972-3-9277232-3


'/>"/>
SOURCE HealthCare Technologies Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today
2. Quest Diagnostics to Speak at the 26th Annual JPMorgan Healthcare Conference
3. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
4. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
5. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
6. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
8. ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008
9. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
10. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
11. AutoGenomics Invited to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Connecticut , November 30, 2016 ... ... Aptuit, LLC today announced that ... library. An additional 150,000 novel compounds have increased the Screening ... to broaden the hit discovery capabilities of the company. This ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader in ... implications of the latest FDA guidance on pharmaceutical cocrystals as drug substance . ... MA. , The event follows the successful November 15th event that took ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... development of a new orally administered treatment for Alzheimer’s disease (AD), today announced ... a Phase 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s patients ...
(Date:11/30/2016)... ... ... With growth rates averaging more than 30% each year, Random42 has quickly ... their expansion in their new office space. The new office has a fantastic location ... creative industries, so Random42 Scientific Communication will fit right in. , Ben Ramsbottom, ...
Breaking Biology Technology:
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):